Published in J Infect Dis on December 14, 2001
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes | NCT00076232
Immunogenetic Modulators of Mucosal Protection From HIV-1 (Kinga) | NCT03701802
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med (2008) 7.49
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62
Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect (2004) 3.49
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. Proc Natl Acad Sci U S A (2005) 2.88
Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One (2015) 2.68
Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol (2004) 2.55
Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transm Infect (2005) 2.55
Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis (2009) 2.23
Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS (2010) 2.17
Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc (2015) 1.93
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe (2009) 1.90
Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med (2009) 1.69
Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. J Acquir Immune Defic Syndr (2007) 1.69
Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother (2003) 1.59
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS (2008) 1.55
Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. Am J Public Health (2009) 1.49
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A (2003) 1.36
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
Associations between herpes simplex virus type 2 and HCV With HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV. Am J Public Health (2011) 1.32
Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol (2011) 1.32
HSV-2: in pursuit of a vaccine. J Clin Invest (2011) 1.29
Group sex events and HIV/STI risk in an urban network. J Acquir Immune Defic Syndr (2008) 1.28
Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sex Transm Infect (2003) 1.27
Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol (2006) 1.26
Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. Sex Transm Infect (2006) 1.26
Alcohol abuse, sexual risk behaviors, and sexually transmitted infections in women in Moshi urban district, northern Tanzania. Sex Transm Dis (2009) 1.25
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS (2009) 1.21
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
Association of age at first sex with HIV-1, HSV-2, and other sexual transmitted infections among women in northern Tanzania. Sex Transm Dis (2009) 1.16
The silent HIV epidemic among pregnant women within rural Northern Tanzania. BMC Public Health (2006) 1.16
Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS (2010) 1.15
Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada. J Clin Microbiol (2003) 1.15
Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: Analyses from the Rakai trials. PLoS Med (2009) 1.13
Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. Sex Transm Dis (2011) 1.12
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 1.10
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One (2014) 1.09
Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine (2008) 1.08
Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection. Virol J (2004) 1.08
Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One (2012) 1.08
New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines (2009) 1.07
Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E. J Virol (2008) 1.07
Circumcision and reduced risk of self-reported penile coital injuries: results from a randomized controlled trial in Kisumu, Kenya. J Urol (2010) 1.07
Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. Elife (2015) 1.07
B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol (2008) 1.06
Sexually transmitted infections among HIV-1-discordant couples. PLoS One (2009) 1.06
Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. Sex Transm Infect (2003) 1.04
In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. Mol Ther Nucleic Acids (2014) 1.03
Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis (2011) 1.02
HIV-1, HSV-2 and syphilis among pregnant women in a rural area of Tanzania: prevalence and risk factors. BMC Infect Dis (2008) 1.02
HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion. J Immunol (2009) 1.02
Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol (2012) 1.01
Latent herpes simplex virus infection of sensory neurons alters neuronal gene expression. J Virol (2003) 1.01
Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother (2011) 1.01
Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol (2010) 1.01
Prevalence and predictors of herpes simplex virus type 2 infection among female sex workers in Yunnan Province, China. Int J STD AIDS (2008) 1.01
Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology (2007) 1.00
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes. Sci Transl Med (2014) 1.00
Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons. Virology (2010) 0.98
Current status and prospects for development of an HSV vaccine. Vaccine (2013) 0.98
The epidemiology of herpes simplex virus type-2 infection among married women in Mysore, India. Sex Transm Dis (2007) 0.97
Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study. BMC Infect Dis (2009) 0.96
Immune modulation during latent herpesvirus infection. Immunol Rev (2012) 0.96
Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts. Clin Vaccine Immunol (2006) 0.95
HSV-2 Infection as a Cause of Female/Male and Racial/Ethnic Disparities in HIV Infection. PLoS One (2013) 0.95
Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med (2013) 0.95
A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis (2010) 0.95
Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin Dev Immunol (2012) 0.93
Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol (2011) 0.93
Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay. J Clin Microbiol (2003) 0.92
Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture. PLoS One (2011) 0.92
Sexually transmitted infections among patients with acute HIV in North Carolina. Sex Transm Dis (2009) 0.92
Secreted portion of glycoprotein g of herpes simplex virus type 2 is a novel antigen for type-discriminating serology. J Clin Microbiol (2003) 0.92
Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India. BMC Infect Dis (2011) 0.91
Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa. Nat Commun (2014) 0.91
The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth. BMC Womens Health (2010) 0.91
Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect (2008) 0.90
Quantitative and qualitative correlates of cervicovaginal herpes simplex virus type 2 shedding among HIV-infected women in the Women's Interagency HIV Study. Int J STD AIDS (2011) 0.89
Herpes simplex virus type 2 infection among commercial sex workers in Kunming, Yunnan Province, China. Int J STD AIDS (2008) 0.89
Gender and age patterns in HSV-2 and HIV infection among non-injecting drug users in New York City. Sex Transm Dis (2010) 0.89
Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides. Mucosal Immunol (2014) 0.89
Understanding natural herpes simplex virus immunity to inform next-generation vaccine design. Clin Transl Immunology (2016) 0.89
The diagnosis of genital herpes - beyond culture: An evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology. Can J Infect Dis Med Microbiol (2007) 0.88
Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania. PLoS One (2013) 0.88
HSV-2 co-infection as a driver of HIV transmission among heterosexual non-injecting drug users in New York City. PLoS One (2014) 0.88
Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis (2010) 0.88
Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology (2008) 0.88
Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2008) 2.33
The effect of surgical site infection on older operative patients. J Am Geriatr Soc (2009) 1.24
The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis (2008) 1.16